From Financial Modeling Prep: 2024-11-16 16:00:04

Agenus Inc. (NASDAQ:AGEN) excels in capital efficiency with a 302.53% ROIC and 80.76% WACC. In contrast, Geron Corporation (NASDAQ:GERN) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) show negative ROIC, indicating capital inefficiencies. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has the highest ROIC to WACC ratio among peers, showing progress towards covering costs.



Read more at Financial Modeling Prep:: Agenus Inc. (NASDAQ:AGEN) Demonstrates Exceptional…